JP4808623B2 - 血管形成を減少させるためのクラスｉｉｉのｓｌｒｐのアゴニスト - Google Patents

血管形成を減少させるためのクラスｉｉｉのｓｌｒｐのアゴニスト Download PDF

Info

Publication number
JP4808623B2
JP4808623B2 JP2006530541A JP2006530541A JP4808623B2 JP 4808623 B2 JP4808623 B2 JP 4808623B2 JP 2006530541 A JP2006530541 A JP 2006530541A JP 2006530541 A JP2006530541 A JP 2006530541A JP 4808623 B2 JP4808623 B2 JP 4808623B2
Authority
JP
Japan
Prior art keywords
class iii
opticin
fgf
slrp
vegf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006530541A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007502855A5 (enExample
JP2007502855A (ja
Inventor
ポール エヌ ビショップ
Original Assignee
ザ ユニヴァーシティー オブ マンチェスター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0312292A external-priority patent/GB0312292D0/en
Priority claimed from GB0400547A external-priority patent/GB0400547D0/en
Application filed by ザ ユニヴァーシティー オブ マンチェスター filed Critical ザ ユニヴァーシティー オブ マンチェスター
Publication of JP2007502855A publication Critical patent/JP2007502855A/ja
Publication of JP2007502855A5 publication Critical patent/JP2007502855A5/ja
Application granted granted Critical
Publication of JP4808623B2 publication Critical patent/JP4808623B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2006530541A 2003-05-29 2004-05-28 血管形成を減少させるためのクラスｉｉｉのｓｌｒｐのアゴニスト Expired - Fee Related JP4808623B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0312292.6 2003-05-29
GB0312292A GB0312292D0 (en) 2003-05-29 2003-05-29 Treatment of blood vessels
GB0400547.6 2004-01-12
GB0400547A GB0400547D0 (en) 2004-01-12 2004-01-12 Treatment of blood vessels
PCT/GB2004/002269 WO2004105784A1 (en) 2003-05-29 2004-05-28 Class iii slrp agonists for the reduction of blood vessel formation

Publications (3)

Publication Number Publication Date
JP2007502855A JP2007502855A (ja) 2007-02-15
JP2007502855A5 JP2007502855A5 (enExample) 2007-07-12
JP4808623B2 true JP4808623B2 (ja) 2011-11-02

Family

ID=33492244

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006530541A Expired - Fee Related JP4808623B2 (ja) 2003-05-29 2004-05-28 血管形成を減少させるためのクラスｉｉｉのｓｌｒｐのアゴニスト

Country Status (8)

Country Link
US (2) US7358224B2 (enExample)
EP (1) EP1638591B1 (enExample)
JP (1) JP4808623B2 (enExample)
DK (1) DK1638591T3 (enExample)
ES (1) ES2408656T3 (enExample)
PL (1) PL1638591T3 (enExample)
PT (1) PT1638591E (enExample)
WO (1) WO2004105784A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004105784A1 (en) 2003-05-29 2004-12-09 The University Of Manchester Class iii slrp agonists for the reduction of blood vessel formation
GB0423273D0 (en) * 2004-10-20 2004-11-24 Univ Manchester Treatment of cancer
GB0724832D0 (en) * 2007-12-20 2008-01-30 Univ Manchester Proteins and nucleic acids
CN102549436A (zh) 2009-07-27 2012-07-04 霍夫曼-拉罗奇有限公司 mimecan在评价心力衰竭中的用途
CA2781309A1 (en) * 2009-12-04 2011-06-09 Euclid Systems Corporation Composition and methods for the prevention and treatment of macular degeneration, diabetic retinopathy, and diabetic macular edema
CN102188694B (zh) * 2010-03-11 2015-05-06 上海交通大学医学院附属瑞金医院 骨生成诱导因子的用途
EP3115784A1 (en) * 2015-07-10 2017-01-11 Koss, Michael Janusz Polypeptide marker for analysis, diagnosis and therapy of eye-related diseases
US20180369325A1 (en) * 2015-11-19 2018-12-27 Garvan Institute Of Medical Research Compounds and methods for treating metabolic disorders
AU2024305223A1 (en) * 2023-06-13 2025-12-18 Rijksuniversiteit Groningen Osteoglycin as regenerative agent for lung tissue

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003511012A (ja) * 1999-09-24 2003-03-25 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ３２個のヒト分泌タンパク質

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5827702A (en) * 1994-10-31 1998-10-27 Genentech, Inc. Ocular gene therapy
DE4445630A1 (de) 1994-12-21 1996-06-27 Forssmann Wolf Georg Humane zirkulierende Peptidfragmente 20-92 und 23-74 des Precursor des Osteoinduktiven Faktors kurz: OIF-20-92 und OIF 23-74
CA2235685A1 (en) 1995-10-23 1997-05-01 Hyal Pharmaceutical Australia Limited Hyaluronic acid as dna carrier for gene therapy and vegf antisense dna to treat abnormal retinal vascularization
ATE343400T1 (de) 1996-09-24 2006-11-15 Merck & Co Inc Verbindungen zur hemmung der angiogenese durch gentherapie
AU5593398A (en) * 1996-12-05 1998-06-29 Alcon Laboratories, Inc. The use of inhibitors of tgf-beta's functions to ameliorate ocular pathology
WO2000068264A2 (en) * 1999-05-10 2000-11-16 The Texas A & M University System A peptide inhibitor of fibrinogen blood clotting
DE60043736D1 (de) * 1999-09-15 2010-03-11 Euclid Systems Corp Zusammensetzung zur stabilisierung des corneagewebon kontaktlinsen
US7304137B2 (en) * 2001-12-13 2007-12-04 The Texas A & M University System Nucleotide and amino acid sequences of asporins
WO2004105784A1 (en) 2003-05-29 2004-12-09 The University Of Manchester Class iii slrp agonists for the reduction of blood vessel formation
GB0423273D0 (en) * 2004-10-20 2004-11-24 Univ Manchester Treatment of cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003511012A (ja) * 1999-09-24 2003-03-25 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ３２個のヒト分泌タンパク質

Also Published As

Publication number Publication date
EP1638591B1 (en) 2013-03-13
WO2004105784A1 (en) 2004-12-09
US20070021334A1 (en) 2007-01-25
US7910567B2 (en) 2011-03-22
EP1638591A1 (en) 2006-03-29
ES2408656T3 (es) 2013-06-21
JP2007502855A (ja) 2007-02-15
US7358224B2 (en) 2008-04-15
DK1638591T3 (da) 2013-06-03
PL1638591T3 (pl) 2013-10-31
PT1638591E (pt) 2013-05-22
US20090130192A1 (en) 2009-05-21

Similar Documents

Publication Publication Date Title
US7910567B2 (en) Opticin nucleic acid administration reduces blood vessel formation
US8906363B2 (en) Fusion proteins for the treatment of CNS
JP6203215B2 (ja) プロミニン−１ペプチド断片およびその使用
JP6046493B2 (ja) プロミニン−１の血管新生促進フラグメントおよびその使用
JP2006503841A (ja) 糖尿病および心血管疾患の治療のためのプロテインキナーゼＣαの抑制
CA2525782C (en) Degradation of glycosaminoglycans in extracellular matrix to treat cns injury
KR20200024263A (ko) 고혈당증의 치료 및 예방을 위한 펩타이드
US20200138903A1 (en) Socs1-derived peptide for use in chronic complications of diabetes
KR101644440B1 (ko) 개선된 혈관신생 억제용 펩티드와 이를 유효성분으로 함유하는 혈관신생과 관련된 질환의 예방 및 치료용 조성물
KR20170122762A (ko) 혈관신생 억제용 펩타이드
JP2020536065A (ja) 興奮性神経毒性に関連した損傷の治療用ペプチド組成物
US20190002517A1 (en) Neuropeptide y-derived peptides
KR20200039621A (ko) 미엘린 장애의 치료를 위한 조성물 및 방법
JP7776492B2 (ja) 心筋損傷の処置または防止に使用するためのペプチド
WO2025106913A1 (en) Peptides for promoting neovascularization and wound healing and methods using the same
US10369187B2 (en) Peptide regulators of JNK family kinases
US20080096793A1 (en) Class III Slrp for the Treatment of Cancer
AU2014265113B2 (en) Fusion proteins for the treatment of cns
KR20220000357A (ko) Prox1 기능 억제제를 유효성분으로 포함하는, 망막신경 퇴행성 질환의 예방 또는 치료용 약학적 조성물
Class et al. Patent application title: NEUROPEPTIDE Y-DERIVED PEPTIDES Inventors: David Paul D. Woldbye (CopenhagenØ, DK) Casper Rene Gøtzsche (Copenhagen Ø, DK) Kristian Klemp (Charlottenlund, DK) Vladimir Berezin (Copenhagen N, DK) Vladimir Berezin (Copenhagen N, DK) Elisabeth Bock (Charlottenlund, DK)
Qi et al. Tissue Inhibitor of Metalloproteinases-3 Peptides Inhibit Angiogenesis and Choroidal
BR112015020143B1 (pt) Composição tópica farmacêutica no tratamento ocular tópico e/ou na prevenção de doenças neurodegenerativas da retina

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070524

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070524

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100607

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100906

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100913

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101006

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101014

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101105

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110328

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110628

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110719

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110817

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140826

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4808623

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees